{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T10:32:14Z","timestamp":1792492334819,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cgfr.co.uk","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.cytogfr.2014.07.017","type":"journal-article","created":{"date-parts":[[2014,7,31]],"date-time":"2014-07-31T23:51:25Z","timestamp":1406850685000},"page":"415-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":134,"title":["IL-12-and IL-23 in health and disease"],"prefix":"10.1016","volume":"25","author":[{"given":"Andrew L.","family":"Croxford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Kulig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Becher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2014.07.017_bib0005","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/eji.201242598","article-title":"IL-23: one cytokine in control of autoimmunity","volume":"42","author":"Croxford","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1189\/jlb.0408228","article-title":"Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy","volume":"88","author":"Krummen","year":"2010","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0015","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/ni1488","article-title":"IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways","volume":"8","author":"Zhou","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0020","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/eji.200939305","article-title":"IL-23-driven encephalo-tropism and Th17 polarization during CNS-inflammation in vivo","volume":"39","author":"Gyulveszi","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0025","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/ni0906-899","article-title":"All in the family: IL-27 suppression of T(H)-17 cells","volume":"7","author":"Colgan","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0030","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1074-7613(02)00324-2","article-title":"IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells","volume":"16","author":"Pflanz","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0035","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/ni.2027","article-title":"RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation","volume":"12","author":"Codarri","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0040","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/ni.2695","article-title":"IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39","volume":"14","author":"Mascanfroni","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0045","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0050","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature12979","article-title":"IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases","volume":"507","author":"Shen","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0055","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1600-065X.2008.00704.x","article-title":"Interleukin-35: odd one out or part of the family?","volume":"226","author":"Collison","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0060","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2337\/db11-0784","article-title":"Prevention of autoimmune diabetes by ectopic pancreatic beta-cell expression of interleukin-35","volume":"61","author":"Bettini","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0092-8674(00)81107-1","article-title":"Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system","volume":"85","author":"Steinman","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0070","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s000180050400","article-title":"Interleukin-12, a key cytokine in Th1-mediated autoimmune diseases","volume":"55","author":"Adorini","year":"1999","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0075","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1084\/jem.20080159","article-title":"IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition","volume":"205","author":"Kroenke","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1084\/jem.181.1.381","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12","volume":"181","author":"Leonard","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0085","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0090","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1172\/JCI0215751","article-title":"Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12","volume":"110","author":"Becher","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0095","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0100","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/ni1539","article-title":"TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology","volume":"8","author":"McGeachy","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0105","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/ni.1698","article-title":"The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo","volume":"10","author":"McGeachy","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0110","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1172\/JCI200319079","article-title":"IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis","volume":"112","author":"Becher","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0115","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(08)70174-1","article-title":"Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis","volume":"7","author":"Martin","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0120","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ni.1610","article-title":"The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat","volume":"9","author":"Manel","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0130","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/jid.2009.399","article-title":"Circulating Th17, Th22, and Th1 cells are increased in psoriasis","volume":"130","author":"Kagami","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0135","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","volume":"113","author":"Austin","year":"1999","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/jid.2008.194","article-title":"Psoriasis is characterized by accumulation of immunostimulatory and Th1\/Th17 cell-polarizing myeloid dendritic cells","volume":"129","author":"Zaba","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0145","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-pathol-011811-132448","article-title":"Psoriasis","volume":"7","author":"Perera","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0150","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdermsci.2009.01.003","article-title":"Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis","volume":"54","author":"Yawalkar","year":"2009","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0155","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.4049\/jimmunol.176.3.1908","article-title":"In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin","volume":"176","author":"Piskin","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0160","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0165","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0170","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0175","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archdermatol.2007.63","article-title":"Safety and efficacy of ABT-874, a fully human interleukin 12\/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial","volume":"144","author":"Kimball","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0180","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/jid.2011.304","article-title":"A phase III, randomized, controlled trial of the fully human IL-12\/23 mAb briakinumab in moderate-to-severe psoriasis","volume":"132","author":"Gordon","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0185","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0190","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0195","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1172\/JCI61862","article-title":"Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice","volume":"122","author":"Pantelyushin","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0200","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0205","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0215","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00439-007-0397-0","article-title":"Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis","volume":"122","author":"Capon","year":"2007","journal-title":"Hum Genet"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0220","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","article-title":"A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0225","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways","volume":"41","author":"Nair","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0230","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.4049\/jimmunol.1100427","article-title":"Cutting edge: identification of a motile IL-17-producing gammadelta T cell population in the dermis","volume":"186","author":"Gray","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0235","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.4049\/jimmunol.1100804","article-title":"Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis","volume":"187","author":"Laggner","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0240","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0245","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0250","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0255","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0260","first-page":"823","article-title":"Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease","volume":"150","author":"Parronchi","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0265","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.MIB.0000194183.92671.b6","article-title":"Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody","volume":"12","author":"Fuss","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0270","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.182.5.1281","article-title":"Antibodies to interleukin 12 abrogate established experimental colitis in mice","volume":"182","author":"Neurath","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0275","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/1521-4141(200201)32:1<261::AID-IMMU261>3.0.CO;2-X","article-title":"Contrasting roles of IL-12p40 and IL-12p35 in the development of hapten-induced colitis","volume":"32","author":"Camoglio","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0280","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.4049\/jimmunol.177.5.2760","article-title":"Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis","volume":"177","author":"Becker","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0285","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.immuni.2010.08.010","article-title":"Interleukin-23 drives intestinal inflammation through direct activity on T cells","volume":"33","author":"Ahern","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0290","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1084\/jem.20101712","article-title":"IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease","volume":"208","author":"Geremia","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0295","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0300","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s10067-005-0106-0","article-title":"Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis","volume":"25","author":"Petrovic-Rackov","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0305","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/rheumatology\/38.11.1058","article-title":"The elevated ratio of interferon gamma-\/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta","volume":"38","author":"Yin","year":"1999","journal-title":"Rheumatology (Oxf)"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0310","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/art.27622","article-title":"Role of Th17 cells in human autoimmune arthritis","volume":"62","author":"Leipe","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0315","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.4049\/jimmunol.1203212","article-title":"Autoreactive Th1 cells activate monocytes to support regional Th17 responses in inflammatory arthritis","volume":"190","author":"Simons","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0320","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.27334","article-title":"LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study","volume":"62","author":"Genovese","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0325","first-page":"93","article-title":"[Use of recombinant human gamma interferon in patients with rheumatoid arthritis]","volume":"45","author":"Seitz","year":"1986","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0330","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/ar2477","article-title":"TH-17 cells in rheumatoid arthritis","volume":"10","author":"Shahrara","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0335","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/art.34339","article-title":"Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12\/interleukin-23 inhibitor, in patients with rheumatoid arthritis","volume":"64","author":"Krausz","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0340","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/14712598.6.12.1323","article-title":"Potential use of IL-2\/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease","volume":"6","author":"Boyman","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0345","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","article-title":"Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis","volume":"102","author":"Mocellin","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl. 1","key":"10.1016\/j.cytogfr.2014.07.017_bib0350","first-page":"S55","article-title":"Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma","volume":"6","author":"Fisher","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0355","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/j.1349-7006.2009.01202.x","article-title":"Cytokine gene-mediated immunotherapy: current status and future perspectives","volume":"100","author":"Jinushi","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0360","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1182\/blood-2005-05-2034","article-title":"Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy","volume":"106","author":"Airoldi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0365","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/jnci\/89.14.1049","article-title":"Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12","volume":"89","author":"Cavallo","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0370","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/ni.1947","article-title":"IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46","volume":"11","author":"Eisenring","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0375","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1084\/jem.188.1.133","article-title":"Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte\/Macrophage colony-stimulating factor","volume":"188","author":"Zilocchi","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0380","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1084\/jem.20130678","article-title":"Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection","volume":"210","author":"Vom Berg","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0385","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1359-6101(01)00032-6","article-title":"Interleukin-12 in anti-tumor immunity and immunotherapy","volume":"13","author":"Colombo","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0390","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.4049\/jimmunol.165.5.2665","article-title":"The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent","volume":"165","author":"Smyth","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0395","first-page":"359","article-title":"Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2\/neu transgenic mice","volume":"60","author":"Boggio","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0400","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0405","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0410","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","article-title":"Stat3\/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer","volume":"19","author":"Lesina","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0415","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ccr.2011.03.002","article-title":"Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression","volume":"19","author":"Fukuda","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0420","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/nm1325","article-title":"Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity","volume":"11","author":"Kortylewski","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0425","doi-asserted-by":"crossref","first-page":"e46264","DOI":"10.1371\/journal.pone.0046264","article-title":"Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression","volume":"7","author":"Li","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0430","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.arcmed.2010.02.009","article-title":"Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma","volume":"41","author":"Ljujic","year":"2010","journal-title":"Arch Med Res"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0435","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature04808","article-title":"IL-23 promotes tumour incidence and growth","volume":"442","author":"Langowski","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0440","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/jcb.24083","article-title":"Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients","volume":"113","author":"Gangemi","year":"2012","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0445","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00535-012-0620-1","article-title":"IL-23R polymorphisms, HBV infection, and risk of hepatocellular carcinoma in a high-risk Chinese population","volume":"48","author":"Xu","year":"2013","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0450","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ijc.26130","article-title":"Potentially functional polymorphisms in IL-23 receptor and risk of esophageal cancer in a Chinese population","volume":"130","author":"Chu","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0455","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/mc.20661","article-title":"A nonsynonymous polymorphism in IL23R gene is associated with risk of gastric cancer in a Chinese population","volume":"49","author":"Chen","year":"2010","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0460","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1084\/jem.20090207","article-title":"IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway","volume":"206","author":"Wang","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0465","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.immuni.2009.09.014","article-title":"T helper 17 cells promote cytotoxic T cell activation in tumor immunity","volume":"31","author":"Martin-Orozco","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0470","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature11465","article-title":"Adenoma-linked barrier defects and microbial products drive IL-23\/IL-17-mediated tumour growth","volume":"491","author":"Grivennikov","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0475","doi-asserted-by":"crossref","first-page":"8328","DOI":"10.1073\/pnas.1003251107","article-title":"IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis","volume":"107","author":"Teng","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0480","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10456-011-9239-8","article-title":"The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate","volume":"15","author":"Pasche","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0485","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1158\/0008-5472.CAN-05-4087","article-title":"Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma","volume":"66","author":"Oniki","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0490","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.molimm.2009.02.025","article-title":"Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma","volume":"46","author":"Hu","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0495","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1182\/blood-2009-10-248245","article-title":"Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells","volume":"116","author":"Cocco","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0500","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/carcin\/bgs384","article-title":"Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor","volume":"34","author":"Li","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0505","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-13-1646","article-title":"Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases","volume":"74","author":"von Scheidt","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0510","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0515","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/gyno.2001.6255","article-title":"Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study","volume":"82","author":"Hurteau","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0520","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1158\/1078-0432.CCR-03-0304","article-title":"Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes","volume":"10","author":"van Herpen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0525","first-page":"75","article-title":"Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma","volume":"4","author":"Bajetta","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0530","first-page":"895s","article-title":"Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12","volume":"7","author":"Gajewski","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0535","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1158\/1535-7163.MCT-09-0820","article-title":"A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2\/neu-expressing malignancies","volume":"8","author":"Bekaii-Saab","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0540","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1200\/JCO.2004.10.045","article-title":"Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma","volume":"22","author":"Alatrash","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0545","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses","volume":"94","author":"Rook","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0550","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1200\/JCO.2007.15.6794","article-title":"Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma","volume":"26","author":"Daud","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0555","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/sj.cgt.7701064","article-title":"Intratumoral injection of IL-12 plasmid DNA \u2013 results of a phase I\/IB clinical trial","volume":"14","author":"Mahvi","year":"2007","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.cytogfr.2014.07.017_bib0560","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.18632\/oncotarget.1853","article-title":"The immunocytokine NHS-IL12 as a potential cancer therapeutic","volume":"5","author":"Fallon","year":"2014","journal-title":"Oncotarget"}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610114000793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610114000793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T16:43:32Z","timestamp":1598114612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610114000793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":112,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1359610114000793"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2014.07.017","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-12-and IL-23 in health and disease","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2014.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}